November Biopharma Financing Report: 90 Companies Secured Investment, Shanghai Leads in Funding

Enterprise Ranking: 90Projects Received Investment

Top 30 Financing Events in the Biopharmaceutical Industry This Month

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

According to the industrial data center of Huoshi Innovation, in November, there were 90 financing events in the biomedical field across China (excluding proposed acquisitions, being acquired, private placements, and IPOs), with a total amount exceeding 3.277 billion yuan (excluding undisclosed amounts). Compared with the previous month, the number of funded projects increased by 21%, and the financing amount rose by 10.14%.

Figure: Financing Situation in the Past 11 Months

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

There were 15 cases with single financing amounts exceeding 100 million yuan, totaling 2.844 billion yuan in financing, accounting for 86.81% of the total financing scale this month.

Figure: Distribution of financing amounts this month

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

In terms of financing rounds, most of the financing events this month were concentrated in Series A, with a total of 20 projects receiving investment. In terms of the amount of financing, Series A+ financing received the highest amount of 844 million yuan, accounting for 25.77% of the total financing amount; followed by Series A, which also received a relatively high amount of 400 million yuan, accounting for 24.46% of the total financing amount.

Figure: Number and Amount of Financing Rounds This Month

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

Institution List: Five Institutions Invest in Multiple Projects

Active Investment Institutions This Month

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

Regional Rankings: Shanghai Tops in Revenue

This month's financing projects are mainly distributed in Jiangsu Province (19 projects) and Zhejiang Province (15 projects). In terms of the amount of financing, Shanghai stands out the most with a total financing amount of 1.464 billion yuan, accounting for 44.69% of the total financing; followed by Jiangsu Province, which also shows prominence with a financing amount reaching 730 million yuan, accounting for 22.28% of the total financing.

Figure: Financing Amount and Number of Deals in Each Region This Month

Source: Huoshi Creation Industry Data Center, Industrial Data Search on Industrial Data Express

The Most Noteworthy Financing Project

C-Ray Therapeutics: Completes Over $100 Million Series A+ Financing

C-Ray Therapeutics, an innovative company in the field of radiopharmaceuticals (Tongrui Biopharmaceutical (Chengdu) Co., Ltd.), announced the completion of an over 100 million USD A+ round of financing. This round was led by SCGC’s New Materials Fund for Manufacturing Transformation and Upgrading, along with Tylon Investment. The funds will primarily be used to further enhance the company's core technology platforms, such as targeted precursor discovery, upgrade high-throughput screening capabilities for innovative RDC drugs, and accelerate the clinical development of multiple world-leading R&D pipelines, especially α radionuclide RDC drugs.

C-Ray Therapeutics was founded in 2021, with its headquarters located in Chengdu Medical City and incubated by Tonghe Yucheng. Since its establishment, the company has been deeply engaged in the field of radiopharmaceuticals, building a nearly 30,000-square-meter R&D and production base for radiopharmaceuticals. It obtained the first Class A Radiation Safety Permit issued to an innovative radiopharmaceutical enterprise and has formed an integrated leading platform with advanced global radiopharmaceutical equipment, technological innovation, and comprehensive functional support. (View related enterprise information on Industrial Data Access.)

BRL Medicine: Completed 200 Million Yuan B+ Round Financing

Shanghai BRL Medicine Inc., which focuses on gene and cell therapy, announced the completion of a nearly 200 million RMB B+ round of financing. This round was led by CSPC Fund, with participation from Beta Fund and other institutions. The funds will be used to advance the clinical translation and market launch of multiple pipeline products, while accelerating the global R&D layout of the product pipeline.

BRL Medicine was founded in 2013 by Professor Mingyao Liu, one of the first scientists recruited back to China through the national talent introduction program. The company is committed to using gene editing to drive innovation, developing breakthrough therapies for cancer, autoimmune diseases, and various other genetic disorders. (Check related company information on Industrial Data Access.)

Zhongsheng Traceability: Completed 150 Million Yuan in Series B Financing

Recently, Zhongsheng Traceability Biotechnology Co., Ltd. has completed the first close of its RMB 150 million Series B financing. This round of financing was led by Guangzhou Industrial Investment, with participation from Zhongyuan Investment, Guju Venture Capital, Hefei Gaotou, and existing shareholder Junlian Capital, among other institutions. The funds will mainly be used to accelerate the clinical development of multiple pipelines in Zhongsheng Traceability's iPSC cell therapy field, as well as subsequent product commercialization.

Zhongsheng溯源, a global pioneer and industry leader in iPSC (induced pluripotent stem cell) technology, was established in 2016. As a national-level specialized and innovative "little giant" enterprise, its headquarters is located in Hefei City, Anhui Province, China. The company focuses on iPSC fundamental research and clinical transformation, committed to developing widely accessible cell therapy products. (View related enterprise information on the Industrial Data Platform.)

Kanglin Bio: Completed A Round Financing of 150 Million Yuan

Kanglin Biotechnology (Hangzhou) Co., Ltd. has just announced the completion of a 150-million-yuan Series A round of financing. This round of financing was jointly invested by Zhejiang Province's "4+1" Biomedical and High-end Equipment Industry Fund and existing shareholder Zhejiang Miyin Investment Management Co., Ltd. The funds will help Kanglin Biotech accelerate the research, development, and commercialization process of gene therapy drugs.

Kanglin Biotech was founded in 2015, focusing on the research and development and commercialization of innovative gene therapy drugs. The company targets diseases that seriously affect human health, such as thalassemia, AIDS, hemophilia, and Parkinson's disease.

       Title: Biopharmaceutical Industry Financing Ranking in November: 90 Companies Received Investment, Shanghai Attracts the Most Capital